| Q34160584 | A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome |
| Q37445320 | Activation of Coagulation and Fibrinolysis in Acute Respiratory Distress Syndrome: A Prospective Pilot Study. |
| Q40901565 | Alveolar surfactant and adult respiratory distress syndrome. Pathogenetic role and therapeutic prospects |
| Q41691907 | Angiopoietin-2 Levels as Predictors of Outcome in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome. |
| Q35794087 | Anti-inflammatory and anticoagulative effects of paeonol on LPS-induced acute lung injury in rats |
| Q42057115 | Antifibrinolytic mechanisms in acute airway injury after sulfur mustard analog inhalation |
| Q36925835 | Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome |
| Q35958312 | Biomarkers in acute lung injury. |
| Q42137123 | Bronchoalveolar Activation of Coagulation and Inhibition of Fibrinolysis during Ventilator-Associated Lung Injury |
| Q42079445 | Development of animal models for the acute respiratory distress syndrome |
| Q36650420 | Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation |
| Q35593180 | Early elevations in B-type natriuretic peptide levels are associated with poor clinical outcomes in pediatric acute lung injury |
| Q36835719 | Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome |
| Q36088869 | Feasibility of tissue plasminogen activator formulated for pulmonary delivery |
| Q34528902 | From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest |
| Q35207771 | Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy |
| Q33762923 | Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia |
| Q37393718 | Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. |
| Q35829051 | Kinetics of lung tissue factor expression and procoagulant activity in bleomycin induced acute lung injury |
| Q47097092 | Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies |
| Q34585962 | Nebulized fibrinolytic agents improve pulmonary fibrinolysis but not inflammation in rat models of direct and indirect acute lung injury |
| Q36494857 | Novel aspects of urokinase function in the injured lung: role of α2-macroglobulin |
| Q36940906 | Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis |
| Q35994453 | Pathophysiology of pulmonary hypertension in acute lung injury. |
| Q37596163 | Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury |
| Q37362031 | Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury |
| Q42799009 | Plasminogen-mediated activation and release of hepatocyte growth factor from extracellular matrix |
| Q37264766 | Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro |
| Q37494702 | Protective mechanisms of activated protein C in severe inflammatory disorders. |
| Q40646976 | Protein C and thrombomodulin in human acute lung injury |
| Q37273851 | Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells |
| Q35126550 | Proteolytic regulation of epithelial sodium channels by urokinase plasminogen activator: cutting edge and cleavage sites |
| Q34302302 | Proteomic profiles in acute respiratory distress syndrome differentiates survivors from non-survivors |
| Q42764805 | Pulmonary coagulopathy: a potential therapeutic target in different forms of lung injury |
| Q26779846 | Reciprocal regulation of TGF-β and reactive oxygen species: A perverse cycle for fibrosis |
| Q24798768 | Surfactant alteration and replacement in acute respiratory distress syndrome |
| Q36225788 | The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor |
| Q36749092 | The inflammation-coagulation axis as an important intermediate pathway in acute lung injury |
| Q37852747 | Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome |
| Q35684759 | Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis |
| Q46917783 | Tranexamic acid attenuates oleic-acid-induced pulmonary extravasation |
| Q33799846 | Transforming growth factor-β1 induces expression of human coagulation factor XII via Smad3 and JNK signaling pathways in human lung fibroblasts |
| Q35684859 | Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice |